The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
The safety of bortezomib for the treatment of multiple myeloma
Abstract
INTRODUCTION: There is now 16 years' worth of established results of various trials demonstrating the bortezomib efficiency in the treatment of multiple myeloma. Over this time, the introduction of bortezomib has been a major break through in the treatment of multiple myeloma. Bortezomib can be administered in the outpatient setting with manageable toxicities. Areas covered: A literature search was carried out using PubMed and Google Scholar. This review gives an overview of the critical role of the bortezomib in multiple myeloma and provides a comprehensive summary of key clinical benefit and safety data with the bortezomib. Initial toxicity profile has improved dramatically with introduction of subcutaneous administration and also, implementation of guidelines for early recognition and treatment. Triplet and quadruplets of bortezomib with agents possessing similar toxicities constitute a challenge. Expert opinion: Bortezomib is an important part of current anti-myeloma therapy with a good clinical efficacy and manageable side effects. Although gastrointestinal disturbances and fatigue are the most common adverse effects, peripheral neuropathy and thrombocytopenia are the key dose-limiting toxicities of bortezomib-based combination regimens. Since these combinations are more effective, with faster disappearance of disease related symptoms and anti-inflammatory effects of bortezomib toxicities were not found to be augmented.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite its efficacy, bortezomib treatment is associated with various side effects, including thrombocytopenia, neutropenia, gastrointestinal toxicity, peripheral neuropathy, infection, and fatigue [48, 149].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [48]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Self-citationHideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,508
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
The proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201
Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908
Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861
Research works printed but not linked: 11
- Schwartz R, 2004, Oncology (Williston Park), 18, 14
- Voorhees PM, 2003, Clin Cancer Res, 9, 6316
- Jung L, 2004, Oncology (Williston Park), 18, 4
- Ma MH, 2003, Clin Cancer Res, 9, 1136
- Hideshima T, 2001, Cancer Res, 61, 3071
- Sunwoo JB, 2001, Clin Cancer Res, 7, 1419
- Nix D, 2003, Paper presented at the 2003 American Association for Cancer Research–National Cancer Institute–European Organization for Research and Treatment of Cancer Molecular Targets and Cancer Therapeutics Discovery, Biology, and Clinical Applications meeting
- Nix D, 2003, Paper presented at the Annual Meeting of the American Association of Pharmaceutical Scientists
- Lu C, 2003, Paper presented at 12th North American Meeting of the International Society for the Study of Xenobiotics
- Jagannath S, 2003, Paper presented at the Annual Meeting of the American Society of Hematology
- Jagannath S, 2006, Haematologica, 91, 929
Cited by
The role of ubiquitination in tumorigenesis and targeted drug discovery
Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Metadata
- Authors
- Cengiz Seval, G., & Beksac, M.
- Affiliations
- Ankara University Medical School, Department of Hematology, Cebeci Hospital, Ankara, Turkey
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2018-08-30
- Volume
- 17
- Issue
- 9
- Pages
- 953-962
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2885850235
- Cited by
- 117
- References
- 65
- Citations by year
- 2026: 7 · 2025: 21 · 2024: 17 · 2023: 18 · 2022: 21 · 2021: 19 · 2020: 10 · 2019: 3
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- bortezomib, multiple myeloma, drug safety, adverse effects, peripheral neuropathy, thrombocytopenia, gastrointestinal toxicity, fatigue, subcutaneous administration, combination chemotherapy, dose-limiting toxicity
- MeSH terms
- Bortezomib, Animals, Antineoplastic Agents, Dose-Response Relationship, Drug, Fatigue, Gastrointestinal Diseases, Humans, Multiple Myeloma, Peripheral Nervous System Diseases, Thrombocytopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The safety of bortezomib for the treatment of multiple myeloma. https://app.cochat.ai/papers/10.1080/14740338.2018.1513487
- The paper
- Cengiz Seval, G., & Beksac, M. (2018). The safety of bortezomib for the treatment of multiple myeloma. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2018.1513487
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
